Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 16/20 | 0.81 |
| ▸ | SRD5A2 | P31213 | 9/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.81 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.81 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.81 |
| ▸ | HSD3B1 | P14060 | 1/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.81 |
| ▸ | THPO | P40225 | 1/20 | 0.81 |
| ▸ | BLM | P54132 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8823373 | 1.00 | SRD5A1 (0.81) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL9308483 | 1.00 | SRD5A1 (0.81) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL9392064 | 0.91 | SRD5A1 (0.81) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL9392054 | 0.91 | SRD5A1 (0.81) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL9392051 | 0.91 | SRD5A1 (0.81) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL22032590 | 0.90 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL21969512 | 0.90 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL5509 | 0.90 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL22564355 | 0.90 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL21969513 | 0.90 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1997032589-A1 | COMBINATIONS FOR TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | claimed |
| WO-1997032604-A1 | ANTIPROLIFERATIVE COMBINATIONS, CONTAINING RAF-TARGETED OLIGONUCLEOTIDES AND CHEMOTHERAPEUTIC COMPOUNDS | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | claimed |
| EP-0538192-B1 | New 17-beta-substituted aza-androstanderivatives | CIBA GEIGY AG (CH) | 1997-04-23 | — | — | EP | claimed |
| US-5304562-A | Inhibitors of 5-alpha-reductase; treating prostate disorders | CIBA-GEIGY CORPORATION (US) | 1994-04-19 | — | — | US | claimed |
| EP-0538192-A1 | New 17-beta-substituted aza-androstanderivatives | CIBA-GEIGY AG (CH) | 1993-04-21 | — | — | EP | claimed |
| US-20030201208-A1 | Dynamic superparamagnetic markers | KOCH, MARTIN (DK) | 2003-10-30 | — | — | US | disclosed |
| US-5744460-A | SYNERGISTIC OF MIXTURE OF PROTEIN KINASE C-TARGETED ANTISENSE OLIGONUCLEOTIDE AND A CHEMOTHERAPEUTIC AGENT, E.G.VINBLASTINE; SIDE EFFECT REDUCTION; ANTICARCINOGENIC- AND TUMOR AGENTS | NOVARTIS CORPORATION (US) | 1998-04-28 | — | — | US | disclosed |
| EP-0538192-B1 | New 17-beta-substituted aza-androstanderivatives | CIBA GEIGY AG (CH) | 1997-04-23 | — | — | EP | disclosed |
| US-5304562-A | Inhibitors of 5-alpha-reductase; treating prostate disorders | CIBA-GEIGY CORPORATION (US) | 1994-04-19 | — | — | US | disclosed |
| EP-0538192-A1 | New 17-beta-substituted aza-androstanderivatives | CIBA-GEIGY AG (CH) | 1993-04-21 | — | — | EP | disclosed |